This is a summary of the European public assessment report (EPAR) for Tookad. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Tookad. For practical information about using Tookad, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy ? 10 years and: - Clinical stage T1c or T2a; - Gleason Score ? 6, based on high-resolution biopsy strategies; - PSA ? 10 ng/mL; - 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ? 50 % cancer involvement in any one core or a PSA density ? 0.15 ng/mL/cm³.
Therapeutic Area (MeSH)
N/AATC Code
L01XD07
ATC Item
padeliporfin
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| padeliporfin di-potassium | N/A | Padeliporfin |
EMA Name
Tookad
Medicine Name
Tookad
Aliases
N/ANo risk management plan link.
